Filing Flows › OptimizeRx (OPRX) › Capital expenditures
OptimizeRx (OPRX) capital expenditures by quarter
OptimizeRx's capital expenditures were $35K in Q2 2026 (second quarter 2026), +218% from Q4 2025. Over the last 6 quarters it ranged from $10K (Q3 2025) to $35K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $35K | +218% | +250% |
| Q4 2025 | $11K | +10% | -35% |
| Q3 2025 | $10K | 0% | — |
| Q2 2025 | $10K | -63% | — |
| Q1 2025 | $27K | +59% | — |
| Q4 2024 | $17K | — | — |
Q2 2026 at a glance
OptimizeRx, Q2 2026: revenue $20.5M (-30% year over year), operating margin -0.4%, net loss $703K, operating cash flow $8.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is OptimizeRx's capital expenditures?
OptimizeRx's capital expenditures were $35K in Q2 2026 (second quarter 2026), +218% from Q4 2025.
How has OptimizeRx's capital expenditures changed?
Over the last 6 quarters it ranged from $10K (Q3 2025) to $35K (Q2 2026).